Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib

MeSH terms

• Adult
• Amino Acid Substitution / physiology
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Benzamides
• Biomarkers, Pharmacological / analysis*
• Biomarkers, Pharmacological / metabolism
• Biomarkers, Tumor / analysis
• Biomarkers, Tumor / genetics
• Biomarkers, Tumor / metabolism
• Dasatinib
• Female
• Fusion Proteins, bcr-abl / genetics*
• Glutamic Acid / genetics
• Humans
• Imatinib Mesylate
• Leucine / genetics
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
• Lysine / genetics
• Mutation, Missense / physiology
• Phenylalanine / genetics
• Piperazines / administration & dosage*
• Polymorphism, Single Nucleotide / physiology
• Pyrimidines / administration & dosage*
• Remission Induction
• Thiazoles / administration & dosage*
• Time Factors
• Treatment Outcome